CD3 directed bispecific antibodies induce increased lymphocyte–endothelial cell interactions in vitro

Bispecific antibody (BsMAb) BIS-1 has been developed to redirect the cytolytic activity of cytotoxic T lymphocytes (CTL) to epithelial glycoprotein-2 (EGP-2) expressing tumour cells. Intravenous administration of BIS-1 F(ab′)(2)to carcinoma patients in a phase I/II clinical trial, caused immunomodul...

Descripción completa

Detalles Bibliográficos
Autores principales: Molema, G, Tervaert, J W Cohen, Kroesen, B J, Helfrich, W, Meijer, D K F, Leij, L F M H de
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363284/
https://www.ncbi.nlm.nih.gov/pubmed/10646907
http://dx.doi.org/10.1054/bjoc.1999.0945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363284/
https://www.ncbi.nlm.nih.gov/pubmed/10646907
http://dx.doi.org/10.1054/bjoc.1999.0945

Ejemplares similares